erythropoietin

(redirected from recombinant erythropoietin)
Also found in: Dictionary, Thesaurus, Encyclopedia.

erythropoietin

 [ĕ-rith″ro-poi´ĕ-tin]
a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis).
recombinant human erythropoietin epoetin.

e·ryth·ro·poi·e·tin (EPO),

(ĕ-rith'rō-poy'ĕ-tin), [MIM*133170]
A protein containing sialic acid that enhances erythropoiesis by stimulating formation of proerythroblasts and release of reticulocytes from bone marrow; it is formed by the kidney and liver, and possibly by other tissues, and can be detected in human plasma and urine.

erythropoietin

/eryth·ro·poi·e·tin/ (-poi´ĕ-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis).
recombinant human erythropoietin  (r-HuEPO) epoetin.

erythropoietin

(ĭ-rĭth′rō-poi-ē′tĭn)
n.
1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.

erythropoietin (EPO)

[erith′rōpō·ē′tin]
Etymology: Gk, erythros + poiein, to make
a glycoprotein hormone synthesized mainly in the kidneys and released into the bloodstream in response to anoxia. The hormone acts to stimulate and to regulate the production of erythrocytes and thus increases the oxygen-carrying capacity of the blood. See also erythropoiesis.

EPO

A gene on chromosome 7q22 that encodes erythropoietin, a secreted, glycosylated cytokine found in the plasma, which regulates red cell production by promoting erythroid differentiation and initiating haemoglobin synthesis. Erythropoietin plays a neuroprotective role in response to brain injury and is antiapoptotic.

Molecular pathology
Genetic variability of EPO has been linked to microvascular complications of diabetes type 2, including diabetic retinopathy, nephropathy leading to end-stage renal disease, and neuropathy

erythropoietin

EPO Physiology A 46 kD glycoprotein colony-stimulating factor produced predominantly by cells adjacent to the proximal renal tubules in response to signals from an oxygen-sensitive substances in the kidneys–eg, heme Adverse effects Chest pain, swelling, tachycardia, headache, HTN; erythropoietin–EP binds to receptors in erythroid precursors that mature into RBCs; EP is ↑ by hypoxia or by ectopic production from tumors–eg, cerebellar hemangioblastoma, hepatoma, pheochromocytoma, uterine leiomyoma, and renal cell carcinoma; it may not be ↑ in anemic premature infants, and is ↓ in 2º anemia, chronic inflammation, P vera, and certain CAs and may be useful in myeloma-related anemia; EP therapy is indicated for HIV-related anemia, anemia of renal failure and prematurity; it ↑ number of units of autologous RBCs that may be donated before surgery, for ↑ number of units that may be phlebotomized in Pts with hemochromatosis and to ↑ units that may be drawn from a person with a rare blood type

e·ryth·ro·poi·e·tin

(ĕ-rith'rō-poy'ĕ-tin)
A protein that enhances erythropoiesis by stimulating formation of proerythroblasts and releasing reticulocytes from bone marrow; secreted mainly by the kidney and possibly by other tissues.

Erythropoietin

A hormone produced by the kidneys that stimulates the production of red blood cells by bone marrow.
Mentioned in: Dialysis, Kidney

erythropoietin

kidney-derived protein promoting erythrocyte formation within bone marrow

erythropoietin

a glycoprotein hormone secreted mainly by the kidney. A profactor, erythropoietinogen, is first produced in the liver, transferred to the kidney and converted to active erythropoietin in the kidney. The erythropoietin acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis). Called also erythropoietin stimulating factor, erythrogenin.

recombinant erythropoietin
used to treat dogs and cats with nonregenerative anemia of renal disease; animals develop antibodies to the human product.
erythropoietin stimulating factor
see erythropoietin (above).
References in periodicals archive ?
2005) Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients.
Amgen revolutionized anemia treatment with the development of Epoetin alfa, a recombinant erythropoietin (a protein that stimulates the production of oxygen-carrying red blood cells).
In addition, antibodies generated to erythropoietin do not cross-react with Hematide, providing a rationale to study it in patients with pure red cell aplasia (PRCA), a rare autoimmune disease caused by development of antibodies to recombinant erythropoietin.
In addition, antibodies generated to erythropoietin do not cross-react with Hematide, providing a rationale to study Hematide in patients with pure red cell aplasia (PRCA), a rare autoimmune disease caused by development of antibodies to recombinant erythropoietin.
Unlike recombinant erythropoietin, Hematide does not produce antibodies to endogenous erythropoietin and may provide improved convenience due to less frequent dosing," said Elizabeth A.
In animal and laboratory studies Hematide has demonstrated an excellent safety and efficacy profile, superior stability, and an extended duration of action compared to currently marketed recombinant erythropoietin products.
In contrast, administration of recombinant erythropoietin (rHuEPO) caused the production of rHuEPO-antibodies in approximately 65% of dosed animals.
To demonstrate the utility of the engineered yeast strains, recombinant erythropoietin (Epo), a protein that stimulates the production of red blood cells, was expressed, purified and its activity demonstrated in vivo.
Antibodies generated experimentally to Hematide do not cross-react with recombinant human erythropoietin and therefore, researchers concluded that Hematide is unlikely to cause pure red cell aplasia and loss of potency for either recombinant erythropoietin receptor agonists or for the patient's endogenous erythropoietin.
OTC BB: DRUG; TSX: DDD; BBSE:DRP) is pleased to announce that Dragon's recombinant Erythropoietin (EPO) products have been granted market approvals in the Dominican Republic and Trinidad-Tobago as advised by Dragon's licensees.

Full browser ?